Corcept Therapeutics Incorporated has completed a Phase III trial investigating the safety and efficacy of mifepristone in patients with Cushing’s syndrome. We have submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval for this indication.

Until approval, we will make mifepristone available to eligible patients in the US through a compassionate use program, aslo known as an Expanded Access Program (EAP). Under compassionate use, the FDA allows seriously ill patients who lack satisfactory alternative treatment options to try a new drug that is still under development.

Interested patients should consult with their physicians. Physicians should call Corcept at 1-877-367-6550 for information about compassionate use or visit our Compassionate Use page.

CONTACT:
1-877-367-6550
EAP@corcept.com